| Filed On | Filing |
|---|---|
| 21 Oct 2026 | 144 |
| 19 Oct 2026 |
Form 3: Bonuccelli Catherine M., Director
No securities owned |
| 19 Oct 2026 | Form 3: Fandrick Keith R., Chief Operating Officer |
| 19 Oct 2026 |
Form 3: Valentine James Elwood, Director
No securities owned |
| 19 Oct 2026 |
Form 3: Wise John Drayton, Director
No securities owned |
| 19 Oct 2026 |
Form 3: Militello John, Chief Financial Officer
No securities owned |
| 19 Oct 2026 |
Form 3: Patterson Leone D, Director
No securities owned |
| 19 Oct 2026 |
8-K: Regulation FD Disclosure
DISCLAIMERS The information in this Presentation has been prepared by IRulya Therapeutics Inc. (formerly Quince Therapeutics, Inc., “IRulya”, and the “company”) and contains information pertaining to the business and operations of the co... |
| 14 Oct 2026 | SCHEDULE 13G |
| 14 Oct 2026 | SCHEDULE 13G |
| 09 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year +2 more
This Executive Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between John Militello (“Executive”) and Quince Therapeutics, Inc. (the “Company”), effective as of September 16, 2026 (the “Effec... |
| 08 Oct 2026 | S-8 |
| 06 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year +1 more
(a) Successor to Prior Plans. The Plan is the successor to the Prior Plans. As of the Effective Date, (i) no additional awards may be granted under the Prior Plans; and (ii) all outstanding awards granted under a Prior Plan will remain s... |
| 02 Oct 2026 | DEFA14A |
| 02 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
On September 30, 2026, each of June Bray, David Lamond and Christopher Senner (collectively, the “Resigning Directors”) tendered conditional resignations from the Board of Directors (the “Board”) of Quince Therapeutics, Inc. (the “Compan... |
| 14 Sep 2026 |
8-K: Completion of Acquisition or Disposition of Assets; Departure/Election of Directors or Officers; Compensation
Quince Therapeutics, Inc., a Delaware corporation (the "Company” or "Seller"), Quince Therapeutics SpA, a company organized under the laws of Italy ("Quince SPA", "Italian Subsidiary") entered into an asset purchase agreement (the "APA")... |
| 04 Sep 2026 | 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule |
| 27 Aug 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 25 Aug 2026 | Proxy statement: special meeting on October 6, 2026 |
| 24 Aug 2026 | EFFECT |
Loading...
